SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

USC and Second Sight Medical Products Inc., the developer of retinal prostheses for treating blindness, are expanding the clinical trial of an advanced retinal prosthesis into Europe. The announcement ...

The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...

A retinal implant system recently approved for sale in the United States could give limited sight to the blind, but a high price tag, challenges with the device and a narrow target group of patients ...

The US Food and Drug Administration (FDA) has announced the approval of a new medical device intended to treat a rare disease population through the use of a retinal implant. The device, Second Sight ...

For more on June 24th's medical story, regarding the woman who lost her vision but is regaining her sight thanks to the system, visit http://www.2-sight.eu/en/product ...

A new final guidance document published by the US Food and Drug Administration (FDA) recommends to sponsors methods of conducting clinical research in support of investigational medical device ...

This undated product image provided by Second Sight Medical Products shows a new implantable device that takes the place of damaged cells inside the eye. The Food and Drug Administration on Thursday, ...

Argus II Retinal Prosthesis fitted patients incurred a discounted incremental cost of 42,455 Euros in comparison to the patient given 'CAU' over the 25 years of time. Progressive improvement in the ...